Suzanne Dahlberg

Research Scientist
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Research

Dr. Dahlberg provides statistical support for clinical trials and collaboration with investigators from the Dana-Farber Acute Lymphoblastic Leukemia Consortium and the Eastern Cooperative Oncology Group's Thoracic Committee.

 

Biography

Ph.D. Harvard University, 2005
B.S.   Tufts University, 2000 

 

Recent Publications

Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: Developing criteria to continue therapy beyond RECIST progression. Cancer 2013; Aug 6 [epub ahead of print].

 

Hoang T, Dahlberg SE, Schiller JH, Johnson DH. Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. Lung Cancer. 2013 Apr 20.

 

Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdière C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, Silverman LB. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20;31(9):1202-10.

 

Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2013 Mar;79(3):283-8.

 

Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84.

 

Lo RC, Darling J, Bensley RP, Giles KA, Dahlberg SE, Hamdan AD, Wyers M, Schermerhorn ML. Long-term outcomes following infrapopliteal angioplasty for critical limb ischemia. J Vasc Surg. 2013 Jan 31.

 

Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD,
Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, Michon B, Laverdière C, Schorin MA, Larsen E, Usmani N, Sallan SE; Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. Pediatrics. 2012 Dec;130(6):1003-11.

 

Shin J, Padmanabhan A, de Groh ED, Lee JS, Haidar S, Dahlberg S, Guo F, He S, Wolman MA, Granato M, Lawson ND, Wolfe SA, Kim SH, Solnica-Krezel L, Kanki JP, Ligon KL, Epstein JA, Look AT. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Dis Model Mech.
2012 Nov;5(6):881-94.

 

Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH.
Prognostic models to predict survival in non-small-cell lung cancer patients
treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol. 2012 Sep;7(9):1361-8.

 

Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, Behrendt K, Koch R, Bishop JF, Dische S, Arriagada R, De Ruysscher D, Pignon JP. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol. 2012 Aug 1;30(22):2788-97.

 

Related Links

ECOG 

DFCI ALL Consortium

National Lung Cancer Partnership